Pharmaceutical company QRxPharma Limited (ASX:QRX) has appointed Dr Edward Rudnic as its new CEO.
Dr Rudnic will replace Dr John Holaday who has been in the role since early 2012.
Dr Rudnic has more than 30 years of senior management and product commercialisation experience working as an executive in the life sciences industry.
The leadership change comes in the wake of the company’s pain relief drug Moxduo failing to gain approval from the US Food and Drug Administration.
QRxPharma reported a net loss of $5.1 million in the first half of the 2014 financial year.
